The past 5–10 years have brought in a new era in the care of patients with thyroid cancer,
with the introduction of transformative diagnostic and management options. Several …

Background: Patients who have metastatic differentiated thyroid cancer (mDTC) frequently
have negative diagnostic and/or post-therapy radioiodine scans. As a result, 131I therapy is …

Background: Before the development of antithyroid drugs in the 1940s, treatment of Graves'
hyperthyroidism was primarily surgical. Surgical mortality was quite variable, but a …

Background: Recently, several studies introduced the potential use of positron emission
tomography/computed tomography (PET/CT) with prostate-specific membrane antigen …

Simple Summary Increased oxidative stress (OS) has been implicated as a relevant risk
factor for cancer development and progression. The incidence of differentiated thyroid …

Patients with thyroid cancer (TC) usually have an excellent prognosis; however, 5–10% of
them develop an advanced disease. The prognosis of this subgroup is still favourable if the …

Thyroid cancer is the most common endocrine malignancy with almost one million people
living with thyroid cancer in the United States. Although early-stage well-differentiated …

Purpose Dosimetry is rarely performed for the treatment of differentiated thyroid cancer
patients with Na [131I] I (radioiodine), and information regarding absorbed doses delivered …

Simple Summary No clinical studies have investigated the effect of radioiodine (131I)-
targeted therapy on the potential markers of ongoing inflammation in patients with DTC …

Differentiated thyroid cancer is the most frequent type of thyroid cancer with an increasing
incidence in the last decades. The initial management is represented by surgical treatment …